EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED

This adverse event was reported 15 times

These drugs are most commonly taken by patients reporting EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED:

# Drug Count
0 DEXAMETHASONE 6
1 DEXAMETHASONE 1.5 MG 6
2 TEMOZOLOMIDE 6
3 BEVACIZUMAB 3
4 GEMCITABINE 2
5 GEMCITABINE HYDROCHLORIDE 2
6 LEVETIRACETAM 2
7 METFORMIN 2
8 METFORMIN ER 500 MG 2
9 METFORMIN ER 750 MG 2
See all common drugs associated with EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED

EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 TEMOZOLOMIDE 6 0.0003
1 TELOTRISTAT ETHYL 1 0.0002
2 GEMCITABINE HYDROCHLORIDE 2 0.0000
3 OXYBUTYNIN 1 0.0000
4 CANAGLIFLOZIN 1 0.0000
5 OCTREOTIDE ACETATE 1 0.0000
6 BEVACIZUMAB 3 0.0000
7 CABOZANTINIB 1 0.0000
8 DEXAMETHASONE 1.5 MG 6 0.0000
9 DEXAMETHASONE 6 0.0000
See all drugs enriched for association with EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED

EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Cholinergic Muscarinic Antagonist [EPC] 1 0.0000
1 Alkylating Drug [EPC] 6 0.0000
2 Vascular Endothelial Growth Factor Inhibitor [EPC] 3 0.0000
3 Dietary Cholesterol Absorption Inhibitor [EPC] 1 0.0000
4 Histamine-2 Receptor Antagonist [EPC] 1 0.0000
5 Platinum-based Drug [EPC] 2 0.0000
6 Calcium [EPC] 1 0.0000
7 Microtubule Inhibitor [EPC] 1 0.0000
8 Expectorant [EPC] 1 0.0000
9 Corticosteroid [EPC] 6 0.0000
See all drug classes enriched for association with EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS IMPROVED